Notícias e Atividades da Syndax Pharmaceuticals

Syndax Pharmaceuticals é uma das ...

• Russell 3000;
• TOB Iconic 10,000.

Syndax Pharmaceuticals é uma empresa listada sob o símbolo SNDX (US).

Veja o organograma con seus 16 executivos principais

Biografias mais buscadas da Syndax Pharmaceuticals

• Michael Metzger, Director and Chief Executive Officer
• Jennifer Jarrett, Director
• Pierre Legault, Director

Recentes movimentos de executivos em Syndax Pharmaceuticals

• Catherine Madigan, Chief Medical Officer, deixará a Companhia em 31 de dez. de 2024  (Notícia publicada em 29 de dezembro de 2024).

Criar um alerta
para seguir os movimentos de executivos da Syndax Pharmaceuticals.

Syndax Pharmaceuticals possui 1.834 concorrentes concorrentes Pfizer (Estados Unidos), Sanofi (França) e Eli Lilly (Estados Unidos).

Popular M&A news in Farmacêutica

• Imbria Pharmaceuticals acaba de anunciar uma arrecadação de fundos de 58 milhões de dólares. (publicado em 10 de abril de 2025).
• Clario adquiriu NRx Pharmaceuticals (publicado em 18 de março de 2025).
• Knight Therapeutics has announced the acquisition of Paladin Labs  (publicado em 12 de março de 2025).

Outros contatos sugeridos na indústria do Farmacêutica

• Estelle Vester-Blokland - Senior Vice President, Medical and Head, International Markets da Bristol-Myers Squibb
• Kristin Berkinsky - Chief Human Resources Officer da Adare Pharmaceuticals
• Seth Harrison - Chairman and Director da Braeburn Pharmaceuticals

Saiba mais sobre a indústria do Farmacêutica

Últimos comunicados de imprensa de Syndax Pharmaceuticals

• Syndax Announces Participation at Stifel Healthcare Conference | Syndax Pharmaceuticals, Inc.
• Syndax Announces Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia Meets Primary Endpoint and Stopped Early for Efficacy Following Protocol-Defined Interim Analysis | Syndax Pharmaceuticals, Inc.
• Syndax to Announce Topline Results from Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia and Host an Investor Call on October 2, 2023 | Syndax Pharmaceuticals, Inc.
• Syndax Announces Participation at the Citi 18th Annual BioPharma Conference | Syndax Pharmaceuticals, Inc.
• Syndax Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Clinical and Business Update | Syndax Pharmaceuticals, Inc.
• Syndax and Incyte Announce Positive Topline Results from the Pivotal AGAVE-201 Trial of Axatilimab in Chronic Graft-Versus-Host Disease | Syndax Pharmaceuticals, Inc.
• Syndax to Announce Second Quarter 2023 Financial Results and Host Conference Call and Webcast on August 3, 2023 | Syndax Pharmaceuticals, Inc.
• Syndax to Announce Second Quarter 2022 Financial Results and Host Conference Call and Webcast on August 8, 2022 | Syndax Pharmaceuticals, Inc.
• Syndax Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) | Syndax Pharmaceuticals, Inc.
• Syndax Pharmaceuticals Announces Appointment of Keith A. Goldan as Chief Financial Officer | Syndax Pharmaceuticals, Inc.
• View more press releases Close

Redes sociais sobre Syndax Pharmaceuticals

• Syndax Pharmaceuticals na Wikipedia, Google News e Yahoo Finance
• Syndax Pharmaceuticals na LinkedIn, Twitter e YouTube